These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16190801)

  • 41. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008559. PubMed ID: 28791693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized, Placebo-Controlled Effectiveness Study of Quetiapine XR in Comorbid Depressive and Anxiety Disorders.
    Ravindran N; McKay M; Paric A; Johnson S; Chandrasena R; Abraham G; Ravindran AV
    J Clin Psychiatry; 2022 Mar; 83(3):. PubMed ID: 35324094
    [No Abstract]   [Full Text] [Related]  

  • 43. The role of quetiapine in the treatment of bipolar disorder.
    Pini S; Abelli M; Cassano GB
    Expert Opin Pharmacother; 2006 May; 7(7):929-40. PubMed ID: 16634715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.
    Gao K; Kemp DE; Fein E; Wang Z; Fang Y; Ganocy SJ; Calabrese JR
    J Clin Psychiatry; 2011 Aug; 72(8):1063-71. PubMed ID: 21034695
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
    Quante A; Regen F; Schindler F; Volkmer K; Severus E; Urbanek C; Luborzewski A; Roepke S; Anghelescu I
    Psychiatr Danub; 2013 Sep; 25(3):214-20. PubMed ID: 24048387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study.
    Mullen J; Jibson MD; Sweitzer D
    Clin Ther; 2001 Nov; 23(11):1839-54. PubMed ID: 11768836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial.
    McConville B; Carrero L; Sweitzer D; Potter L; Chaney R; Foster K; Sorter M; Friedman L; Browne K
    J Child Adolesc Psychopharmacol; 2003; 13(1):75-82. PubMed ID: 12804128
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
    Bauer M; Thase ME; Liu S; Earley W; Eriksson H
    J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
    Barber S; Olotu U; Corsi M; Cipriani A
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006324. PubMed ID: 28333365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quetiapine fumarate extended-release for the treatment of major depression with comorbid fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study.
    McIntyre A; Paisley D; Kouassi E; Gendron A
    Arthritis Rheumatol; 2014 Feb; 66(2):451-61. PubMed ID: 24504819
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders.
    Corson AH; Barkenbus JE; Posey DJ; Stigler KA; McDougle CJ
    J Clin Psychiatry; 2004 Nov; 65(11):1531-6. PubMed ID: 15554768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of quetiapine in bipolar disorder: a case series with prospective evaluation.
    Suppes T; McElroy SL; Keck PE; Altshuler L; Frye MA; Grunze H; Leverich GS; Nolen WA; Chisholm K; Dennehy EB; Post RM
    Int Clin Psychopharmacol; 2004 May; 19(3):173-4. PubMed ID: 15107662
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine.
    Duffy A; Milin R; Grof P
    BMC Psychiatry; 2009 Feb; 9():4. PubMed ID: 19200370
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Second-generation antipsychotics for anxiety disorders.
    Depping AM; Komossa K; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008120. PubMed ID: 21154392
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
    Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
    J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
    Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder.
    DelBello MP; Adler CM; Whitsel RM; Stanford KE; Strakowski SM
    J Clin Psychiatry; 2007 May; 68(5):789-95. PubMed ID: 17503991
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy.
    Bauer M; McIntyre RS; Szamosi J; Eriksson H
    Int J Neuropsychopharmacol; 2013 Sep; 16(8):1755-65. PubMed ID: 23672772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.